Thus, using an MEK inhibitor (trametinib) in combination with the adipogenesis-inducer rosiglitazone for adipogenic transdifferentiation therapy strongly promoted the direct spectrum transformation of these cancer cells and prevented their invasion and metastasis. This evidence concerns the gene MAP2K7 and cancer.